REGISTER
When to Reduce Lorlatinib in ALK-Positive NSCLC? | Geoffrey Liu, WCLC 2026
At WCLC 2026, Prof. Geoffrey Liu of Princess Margaret Cancer Centre discusses the seven-year CROWN update in ALK-positive NSCLC. The interview explores the long-term safety of first-line lorlatinib, early management of adverse events, and the role of treatment interruption and dose reduction. Prof. Liu also considers how sustained disease control is reshaping long-term care and future research priorities.

At WCLC 2026, Prof. Geoffrey Liu discusses the seven-year CROWN safety update and practical strategies for sustaining first-line lorlatinib treatment in ALK-positive NSCLC.

Organized by the International Association for the Study of Lung Cancer, WCLC 2026 took place in Seoul, Republic of Korea, from September 12 to 15.

Prof. Geoffrey Liu is a Professor at the University of Toronto and a Staff Physician at Princess Margaret Cancer Centre, University Health Network.

Key highlights from this clip:

● Why adverse events require the closest monitoring and most active management during the first two years

● How early intervention for weight gain and central nervous system effects may improve long-term tolerability

● When temporary treatment interruption and dose reduction should be considered

● Why early dose reductions were associated with similar progression-free survival and intracranial control in the CROWN analysis

● How longer disease control is changing follow-up and quality-of-life considerations

● Research priorities for patients who experience early disease progression, including combination strategies and ctDNA monitoring This video is intended for medical education and professional discussion.

0
0
Loading